Market closed
Astria Therapeutics/$ATXS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Astria Therapeutics
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Ticker
$ATXS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
59
Website
ATXS Metrics
BasicAdvanced
$533M
Market cap
-
P/E ratio
-$1.97
EPS
0.71
Beta
-
Dividend rate
Price and volume
Market cap
$533M
Beta
0.71
52-week high
$16.90
52-week low
$5.94
Average daily volume
321K
Financial strength
Current ratio
22.377
Quick ratio
21.895
Long term debt to equity
1.247
Total debt to equity
1.65
Management effectiveness
Return on assets (TTM)
-22.72%
Return on equity (TTM)
-38.03%
Valuation
Price to book
2.16
Price to tangible book (TTM)
2.16
Price to free cash flow (TTM)
-5.082
Growth
Earnings per share change (TTM)
-7.59%
3-year earnings per share growth (CAGR)
-61.18%
What the Analysts think about ATXS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Astria Therapeutics stock.
ATXS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ATXS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ATXS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Astria Therapeutics stock?
Astria Therapeutics (ATXS) has a market cap of $533M as of December 21, 2024.
What is the P/E ratio for Astria Therapeutics stock?
The price to earnings (P/E) ratio for Astria Therapeutics (ATXS) stock is 0 as of December 21, 2024.
Does Astria Therapeutics stock pay dividends?
No, Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Astria Therapeutics dividend payment date?
Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Astria Therapeutics?
Astria Therapeutics (ATXS) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.